Sanofi (SAN) PT Set at €75.00 by Jefferies Financial Group

Share on StockTwits

Sanofi (EPA:SAN) has been given a €75.00 ($87.21) price objective by stock analysts at Jefferies Financial Group in a note issued to investors on Friday. The brokerage presently has a “neutral” rating on the stock. Jefferies Financial Group’s target price would suggest a potential upside of 13.34% from the company’s previous close.

Several other research analysts also recently issued reports on the stock. BNP Paribas set a €87.00 ($101.16) target price on shares of Sanofi and gave the stock a “buy” rating in a research note on Tuesday, September 11th. Deutsche Bank set a €87.00 ($101.16) target price on shares of Sanofi and gave the stock a “buy” rating in a research note on Thursday, September 6th. Bank of America set a €95.00 ($110.47) target price on shares of Sanofi and gave the stock a “buy” rating in a research note on Monday, September 10th. Goldman Sachs Group set a €74.00 ($86.05) price objective on shares of Sanofi and gave the company a “neutral” rating in a research report on Thursday, June 14th. Finally, Citigroup set a €93.00 ($108.14) price objective on shares of Sanofi and gave the company a “buy” rating in a research report on Friday, August 10th. Two analysts have rated the stock with a sell rating, ten have given a hold rating and seven have issued a buy rating to the stock. Sanofi currently has a consensus rating of “Hold” and an average price target of €79.16 ($92.04).

Shares of EPA SAN opened at €66.17 ($76.94) on Friday. Sanofi has a 52-week low of €63.09 ($73.36) and a 52-week high of €92.97 ($108.10).

Sanofi Company Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an oral immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

See Also: What is a stock buyback?

Analyst Recommendations for Sanofi (EPA:SAN)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.